Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study

Table 2

Changes in UACR, HbA1c, eGFR, and lipid profiles 1 year before and 1 year after DPP-4i treatment initiation.

	Changes during; 1 year before treatment	Changes during; 1 year after treatment	p value^‡
UACR (mg/g)	40.8 ± 307.8	−44.5 ± 351.9	<0.05
HbA1c (%)	0.4 ± 1.1	−0.8 ± 1.5	<0.01
Systolic blood pressure (mmHg)	−1.2 ± 20.5	1.9 ± 20.7	0.13
Diastolic blood pressure (mmHg)	−0.3 ± 12.8	1.4 ± 12.7	0.37
LDL-cholesterol (mg/dL)	−1.2 ± 26.32	−3.5 ± 30.2	<0.05
HDL-cholesterol (mg/dL)	−0.3 ± 8.7	−0.9 ± 8.4	0.30
eGFR (mL/min/1.73 m^2)	−0.7 ± 8.7	1.2 ± 11.3	0.69

Data are presented as means ± standard deviation.
^‡The paired Student’s -test was performed to evaluate changes in each parameter from baseline to 1 year before DPP-4i treatment and 1 year after treatment initiation.
DPP-4i: dipeptidyl-peptidase IV inhibitor; eGFR: estimated glomerular filtration rate; HbA1c: glycosylated hemoglobin; HDL: high density lipoprotein; LDL: low density lipoprotein; UACR: urine albumin/creatinine ratio.